US Bancorp DE Has $1.65 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

US Bancorp DE increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 21.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,332 shares of the company’s stock after purchasing an additional 21,744 shares during the quarter. US Bancorp DE’s holdings in Takeda Pharmaceutical were worth $1,646,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in TAK. FMR LLC increased its position in Takeda Pharmaceutical by 10.9% in the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after acquiring an additional 286,052 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Takeda Pharmaceutical by 1.6% in the fourth quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock worth $29,266,000 after purchasing an additional 35,192 shares in the last quarter. Managed Asset Portfolios LLC lifted its position in shares of Takeda Pharmaceutical by 0.3% in the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock worth $23,001,000 after purchasing an additional 4,069 shares in the last quarter. Stifel Financial Corp raised its position in Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after acquiring an additional 224,594 shares in the last quarter. Finally, Pathstone Holdings LLC raised its position in Takeda Pharmaceutical by 1.0% during the third quarter. Pathstone Holdings LLC now owns 430,676 shares of the company’s stock worth $6,124,000 after acquiring an additional 4,280 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $15.18 on Friday. The firm has a market capitalization of $48.29 billion, a P/E ratio of 37.94, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The firm’s fifty day moving average price is $13.59 and its two-hundred day moving average price is $13.91. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.22. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.